Recently, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have jointly released an expert opinion-based Consensus Report1,2 on precision diabetes medicine deliberating particularly about the precision diagnosis and the precision therapeutics. This Consensus Report functions as the starting point for a series of activities including systematic review of evidence, dissemination of findings, conduct of international research and educational symposia, and development of clinical guidelines—planned in a phased manner from 2018 to 2025 and beyond. These proposed activities are the reflections of the key objectives set forth by the Precision Medicine in Diabetes Initiative (PMDI). The PMDI (2018) was established by the ADA in collaboration with the EASD, and its vision statement is “realizing a future of longer, healthier lives for people with diabetes, achieved by applying the appropriate (right) treatment for the appropriate (right) person at the appropriate (right) time.” 3 The PMDI Task Force encompasses both the Executive Oversight Committee, which functions as the governing body, and the Steering Committee, which functions as the guiding body for PMDI activities.
展开▼
